z-logo
open-access-imgOpen Access
Calcium signaling in systemic lupus erythematosus T cells: A treatment target
Author(s) -
Kyttaris Vasileios C.,
Zhang Zheng,
Kampagianni Ourania,
Tsokos George C.
Publication year - 2011
Publication title -
arthritis & rheumatism
Language(s) - English
Resource type - Journals
eISSN - 1529-0131
pISSN - 0004-3591
DOI - 10.1002/art.30353
Subject(s) - medicine , dipyridamole , calcineurin , immunology , t cell , systemic lupus erythematosus , cd8 , lupus erythematosus , endocrinology , antibody , cd3 , immune system , transplantation , disease
Objective Systemic lupus erythematosus (SLE) T cells display a hyperactive calcineurin/NF‐AT pathway. The aim of this study was to determine whether this pathway is responsible for the aberrant SLE T cell function and to test the effectiveness of the recently recognized calcineurin inhibitor dipyridamole in limiting SLE‐related pathology. Methods T cells and mononuclear cells were isolated from the peripheral blood of SLE patients and healthy individuals. Murine cells were isolated from the spleens and lymph nodes of lupus‐prone MRL/ lpr mice and control MRL/MpJ mice. Cells were treated in vitro with tacrolimus, dipyridamole, or control. MRL/ lpr mice were injected intraperitoneally with 50 mg/kg of dipyridamole 3 times a week for 3 weeks. Results MRL/ lpr T cells, especially CD3+CD4–CD8– cells, displayed a robust calcium influx upon activation and increased levels of NF‐ATc1. MRL/ lpr T cells (both CD4+ and CD3+CD4–CD8– cells) provided help to B cells to produce immunoglobulin in a calcineurin‐dependent manner. Dipyridamole treatment of SLE T cells significantly inhibited CD154 expression, interferon‐γ, interleukin‐17 (IL‐17), and IL‐6 production, and T cell–dependent B cell immunoglobulin secretion. Treatment of MRL/ lpr mice with dipyridamole alleviated lupus nephritis and prevented the appearance of skin ulcers. Conclusion NF‐AT activation is a key step in the activation of SLE T cells and the production of immunoglobulin. Dipyridamole inhibits SLE T cell function and improves pathologic changes of the disease in lupus‐prone mice. We propose that dipyridamole can be used in treatment regimens for patients with SLE.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here